Inicio
Markets
Charts & Ideas
Algo
Noticias
Store
Corredores
Descargar
Calendario económico
Señales Comerciales
WebTerminal
Pulse
/
para buscar: @user, $symbol, ...
Buscar
Entrada
Crear una cuenta
Português
English
Русский
中文
Español
日本語
Deutsch
한국어
Français
Italiano
Türkçe
ADAG
#3090
Adagene Inc. American Depositary Shares
2.9
6
-7.21%
Sector:
Básica:
Profit Currency:
Rango diario
Rango anual
Cambio diario
-7.21%
Monthly Change
+24.37%
6 month change
+37.67%
Cambio anual
+42.31%
Cierres anteriores
3.1
9
Open
2.9
6
Bid
Ask
Low
2.9
6
High
2.9
6
Volumen
1
Markets
Acciones
Atención Sanitaria
ADAG
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
Q4, 24
TTM
Key stats
Total common shares outstanding
58.89 M
222.69 M
Valuation ratios
Enterprise value
37.28 M
275.25 M
Price to earnings ratio
-3.37
-15.36
Price to sales ratio
—
—
Price to cash flow ratio
-3.77
-18.25
Price to book ratio
2.22
7.14
Enterprise value to EBITDA ratio
—
—
Profitability ratios
Return on assets %
-0.01
0.07
Return on equity %
-0.01
0.11
Return on invested capital %
—
—
Gross margin %
—
—
Operating margin %
—
—
EBITDA margin %
—
—
Net margin %
—
—
Liquidity ratios
Quick ratio
—
—
Current ratio
2.3
14.85
Inventory turnover
—
—
Asset turnover
—
—
Solvency ratios
Debt to assets ratio
0.06
0.41
Debt to equity ratio
0.1
0.7
Long term debt to total assets ratio
0
0.23
Long term debt to total equity ratio
0.01
0.39
Per share metrics
Operating cash flow per share
-0.01
0.27
EBIT per share
—
—
EBITDA per share
—
—
Total debt per share
0.09
1
Cash per share
1.51
9.66
Net current asset value per share
1.56
10.11
Tangible book value per share
0.9
6.85
Working capital per share
0.88
7.24
Book value per share
0.9
6.85
Noticias
Moderna's Shares Climb 5.3% as Investors Revisit Biotech Leaders
FDA Grants Fast Track Designation to ADAG's Colorectal Cancer Drug
Ações da Adagene disparam após FDA conceder status de Via Rápida para terapia contra câncer
Adagene stock soars after FDA grants Fast Track status for cancer therapy
FDA concede status de via rápida ao muzastotug da Adagene para câncer colorretal
FDA grants fast track status to Adagene’s muzastotug for colorectal cancer
Adagene administra primeiro paciente em estudo de fase 2 do muzastotug para CCR MSS
Adagene doses first patient in Phase 2 trial of muzastotug for MSS CRC
All You Need to Know About Adagene (ADAG) Rating Upgrade to Buy
Are Medical Stocks Lagging Adagene (ADAG) This Year?
Ações da Adani sobem após SEBI descartar acusações da Hindenburg
Adani shares rally as SEBI dismisses Hindenburg allegations